Israel Englander’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-509,647
| Closed | -$113M | – | 5774 |
|
|
2025
Q4 | $113M | Buy |
509,647
+321,364
| +171% | +$51.9M | 0.05% | 388 |
|
|
2025
Q3 | $18M | Buy |
+188,283
| New | +$12M | 0.01% | 1777 |
|
|
2025
Q2 | – | Sell |
-63,580
| Closed | -$1.37M | – | 5899 |
|
|
2025
Q1 | $1.37M | Buy |
63,580
+27,620
| +77% | +$614K | ﹤0.01% | 4119 |
|
|
2024
Q4 | $967K | Buy |
35,960
+22,041
| +158% | +$358K | ﹤0.01% | 4225 |
|
|
2024
Q3 | $150K | Buy |
+13,919
| New | +$167K | ﹤0.01% | 5510 |
|
|
2023
Q3 | – | Sell |
-5,960
| Closed | -$135K | – | 6164 |
|
|
2023
Q2 | $135K | Buy |
+5,960
| New | +$140K | ﹤0.01% | 5254 |
|
|
2023
Q1 | – | Sell |
-34,496
| Closed | -$522K | – | 6410 |
|
|
2022
Q4 | $522K | Buy |
34,496
+30,310
| +724% | +$362K | ﹤0.01% | 4715 |
|
|
2022
Q3 | $53K | Buy |
4,186
+1,603
| +62% | +$22.1K | ﹤0.01% | 6169 |
|
|
2022
Q2 | $25K | Buy |
2,583
+325
| +14% | +$4.01K | ﹤0.01% | 6429 |
|
|
2022
Q1 | $38K | Sell |
2,258
-2,031
| -47% | -$34.4K | ﹤0.01% | 6474 |
|
|
2021
Q4 | $109K | Sell |
4,289
-11,618
| -73% | -$362K | ﹤0.01% | 6220 |
|
|
2021
Q3 | $713K | Sell |
15,907
-13,133
| -45% | -$499K | ﹤0.01% | 5007 |
|
|
2021
Q2 | $1.17M | Buy |
29,040
+25,851
| +811% | +$1.09M | ﹤0.01% | 4518 |
|
|
2021
Q1 | $170K | Sell |
3,189
-6,779
| -68% | -$335K | ﹤0.01% | 5539 |
|
|
2020
Q4 | $399K | Buy |
+9,968
| New | +$496K | ﹤0.01% | 4376 |
|
|
2020
Q2 | – | Sell |
-2,684
| Closed | -$133K | – | 4197 |
|
|
2020
Q1 | $133K | Sell |
2,684
-2,050
| -43% | -$123K | ﹤0.01% | 3493 |
|
|
2019
Q4 | $364K | Buy |
+4,734
| New | +$217K | ﹤0.01% | 3562 |
|
|
2019
Q3 | – | Sell |
-9,457
| Closed | -$318K | – | 4196 |
|
|
2019
Q2 | $318K | Sell |
9,457
-1,919
| -17% | -$79.7K | ﹤0.01% | 3514 |
|
|
2019
Q1 | $603K | Buy |
11,376
+835
| +8% | +$45.8K | ﹤0.01% | 3152 |
|
|
2018
Q4 | $495K | Sell |
10,541
-11,312
| -52% | -$807K | ﹤0.01% | 2978 |
|
|
2018
Q3 | $1.92M | Sell |
21,853
-14,288
| -40% | -$1.26M | ﹤0.01% | 2461 |
|
|
2018
Q2 | $3.76M | Buy |
36,141
+6,658
| +23% | +$629K | ﹤0.01% | 1987 |
|
|
2018
Q1 | $2.36M | Sell |
29,483
-195
| -0.7% | -$26.6K | ﹤0.01% | 2216 |
|
|
2017
Q4 | $4.04M | Sell |
29,678
-552
| -2% | -$83.7K | 0.01% | 1860 |
|
|
2017
Q3 | $4.9M | Buy |
30,230
+768
| +3% | +$109K | 0.01% | 1689 |
|
|
2017
Q2 | $4.42M | Buy |
29,462
+18,698
| +174% | +$2.58M | 0.01% | 1588 |
|
|
2017
Q1 | $1.68M | Buy |
10,764
+7,475
| +227% | +$1.31M | ﹤0.01% | 2102 |
|
|
2016
Q4 | $684K | Buy |
+3,289
| New | +$684K | ﹤0.01% | 2481 |
|
|
2015
Q4 | – | Sell |
-2,975
| Closed | -$757K | – | 3434 |
|
|
2015
Q3 | $757K | Sell |
2,975
-2,895
| -49% | -$828K | ﹤0.01% | 2440 |
|
|
2015
Q2 | $1.65M | Buy |
+5,870
| New | +$1.81M | ﹤0.01% | 2028 |
|
Israel Englander's CDTX Position: Q1 2026 in Review
Israel Englander sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 509,647 shares — an estimated $113M sold.
Israel Englander first reported a position in CDTX in Q2 2015 and held it in 30 quarters. The position peaked at $113M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Israel Englander reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Israel Englander sold 509,647 Cidara Therapeutics shares in Q1 2026, an estimated $113M.
- Israel Englander first reported a position in Cidara Therapeutics in Q2 2015 and held it in 30 quarters.
- Israel Englander's Cidara Therapeutics position peaked at $113M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.